Activity of Brigatinib in Alectinib-Resistant ALK-Positive NSCLC According to ALK Plasma Mutation Status From J-ALTA Trial

被引：0
作者：
Hida, T. [1 ]
Katayama, R. [2 ]
Nishio, M. [3 ]
Yoshida, T. [4 ]
Kumagai, T. [5 ]
Toyozawa, R. [6 ]
Shimokawaji, T. [7 ]
Goto, K. [8 ]
Nakagawa, K. [9 ]
Seto, T. [10 ]
Yamamoto, N. [11 ]
Asato, T. [12 ]
Hiraoka, K. [13 ]
Zhang, P. [14 ]
Ohe, Y. [15 ]
机构：
[1] Aichi Canc Ctr, Dept Thorac Oncol, Nagoya, Aichi, Japan
[2] Japanese Fdn Canc Res, Div Expt Chemotherapy, Ctr Canc Chemotherapy, Tokyo, Japan
[3] Japanese Fdn Canc Res, Dept Thorac Med Oncol, Canc Inst Hosp, Tokyo, Japan
[4] Natl Canc Ctr, Thorac Oncol, Tokyo, Japan
[5] Osaka Int Canc Inst, Dept Thorac Oncol, Osaka, Japan
[6] Natl Hosp Org Kyushu Canc Ctr, Fukuoka, Japan
[7] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan
[8] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Chiba, Japan
[9] Kindai Univ, Fac Med, Dept Med Oncol, Higashiosaka, Osaka, Japan
[10] NHO Kyushu Canc Ctr, Thorac Oncol, Fukuoka, Japan
[11] Wakayama Med Univ, Wakayama, Japan
[12] Takeda Pharmaceut Co Ltd, Oncol Therapeut Area Unit Japan & Asia, Tokyo, Japan
[13] Takeda Pharmaceut Co Ltd, Japan Oncol Business Unit, Tokyo, Japan
[14] Millennium Pharmaceut Inc, Cambridge, MA USA
[15] Natl Canc Ctr, Tokyo, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
brigatinib; alectinib-resistant; ALK-positive NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P75.01
引用
收藏
页码：S572 / S572
页数：1
相关论文
共 10 条
  • [1] Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial
    Nishio, Makoto
    Yoshida, Tatsuya
    Kumagai, Toru
    Hida, Toyoaki
    Toyozawa, Ryo
    Shimokawaji, Tadasuke
    Goto, Koichi
    Nakagawa, Kazuhiko
    Ohe, Yuichiro
    Seto, Takashi
    Kudou, Kentarou
    Asato, Takayuki
    Zhang, Pingkuan
    Yamamoto, Nobuyuki
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : 452 - 463
  • [2] Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC
    Lin, Jessica J.
    Zhu, Viola W.
    Schoenfeld, Adam J.
    Yeap, Beow Y.
    Saxena, Ashish
    Ferris, Lorin A.
    Dagogo-Jack, Ibiayi
    Farago, Anna F.
    Taber, Angela
    Traynor, Anne
    Menon, Smitha
    Gainor, Justin F.
    Lennerz, Jochen K.
    Plodkowski, Andrew J.
    Digumarthy, Subba R.
    Ignatius, Sai-Hong
    Shaw, Alice T.
    Riely, Gregory J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : 1530 - 1538
  • [3] The Optimal ALK inhibitor in Advanced ALK-Positive NSCLC Patients: An Indirect Comparison Between Brigatinib and Alectinib
    Chen, G.
    Zhang, Y.
    Zhou, H.
    Zhao, S.
    Liu, J.
    Hong, S.
    Zhang, L.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1056 - S1056
  • [4] Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial
    Yang, James Chih-Hsin
    Liu, Geoffrey
    Lu, Shun
    He, Jianxing
    Burotto, Mauricio
    Ahn, Myung-Ju
    Kim, Dong-Wan
    Liu, Xiaoqing
    Zhao, Yanqiu
    Vincent, Sylvie
    Yin, Jiani
    Ma, Xin
    Lin, Huamao M.
    Popat, Sanjay
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (12) : 1743 - 1755
  • [5] Brigatinib in Japanese patients with ALK-positive non-small-cell lung cancer: Final results of the phase 2 J-ALTA trial
    Yoshida, Tatsuya
    Kumagai, Toru
    Toyozawa, Ryo
    Katayama, Ryohei
    Nishio, Makoto
    Seto, Takashi
    Goto, Koichi
    Yamamoto, Nobuyuki
    Ohe, Yuichiro
    Kudou, Kentarou
    Asato, Takayuki
    Zhang, Pingkuan
    Nakagawa, Kazuhiko
    CANCER SCIENCE, 2023, 114 (09) : 3698 - 3707
  • [6] Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial
    Camidge, D. Ross
    Kim, Hye Ryun
    Ahn, Myung-Ju
    Yang, James C. H.
    Han, Ji-Youn
    Hochmair, Maximilian J.
    Lee, Ki Hyeong
    Delmonte, Angelo
    Campelo, Maria Rosario Garcia
    Kim, Dong-Wan
    Griesinger, Frank
    Felip, Enriqueta
    Califano, Raffaele
    Spira, Alexander I.
    Gettinger, Scott N.
    Tiseo, Marcello
    Lin, Huamao M.
    Liu, Yuyin
    Vranceanu, Florin
    Niu, Huifeng
    Zhang, Pingkuan
    Popat, Sanjay
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (12) : 2091 - 2108
  • [7] ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib
    Kim, Edward S.
    Barlesi, Fabrice
    Mok, Tony
    Ahn, Myung-Ju
    Shen, Junwu
    Zhang, Pingkuan
    Ou, Sai-Hong Ignatius
    FUTURE ONCOLOGY, 2021, 17 (14) : 1709 - 1719
  • [8] Brigatinib in Crizotinib-Refractory ALK plus NSCLC: Updated Efficacy and Safety Results From ALTA, a Randomized Phase 2 Trial
    Ahn, M.
    Camidge, D. R.
    Tiseo, M.
    Reckamp, K.
    Hansen, K.
    Kim, S.
    Huber, R.
    West, H.
    Groen, H.
    Hochmair, M.
    Leighl, N.
    Gettinger, S.
    Langer, C.
    Paz-Ares, L.
    Smit, E.
    Kim, E.
    Reichmann, W.
    Kerstein, D.
    Kim, D.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1755 - S1756
  • [9] Brigatinib in Crizotinib-Refractory ALK plus NSCLC: Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial
    Camidge, D. Ross
    Tiseo, Marcello
    Ahn, Myung-Ju
    Reckamp, Karen
    Hansen, Karin
    Kim, Sang-We
    Huber, Rudolf
    West, Howard
    Groen, Harry
    Hochmair, Maximilian
    Leighl, Natasha
    Gettinger, Scott
    Langer, Corey
    Paz-Ares, Luis
    Smit, Egbert
    Kim, Edward
    Reichmann, William
    Clackson, Tim
    Kerstein, David
    Haluska, Frank
    Kim, Dong-Wan
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1167 - S1169
  • [10] Real-World Outcomes of 2L ALK TKIs Following 1L Brigatinib for Patients with ALK plus NSCLC from the ALTA-1L Trial
    Ahn, M. -J.
    Delmonte, A.
    Ghosh, S.
    Hochmair, M.
    Yang, T. -Y.
    Yang, J. C. -H.
    Han, J. -Y.
    Hansen, K. Holmskov
    Wu, Y.
    Wan, Y.
    Lin, H. M.
    Kretz, J.
    Hupf, B.
    Kurec, A. M.
    Churchill, E. N.
    Fram, R. J.
    Cabasag, C. J.
    Goriya, V.
    Zhao, Y.
    Gemmen, E.
    Campelo, M. R. Garcia
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S200 - S200
1